Beta Bionics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 |
|---|---|---|---|
| Revenue | $100.3M | $65.1M | $12.0M |
| Gross profit | $55.5M | $35.9M | $6.3M |
| Operating income | -$71.7M | -$45.3M | -$35.9M |
| Operating expenses | $127.2M | $81.1M | $42.2M |
| Cost of revenue | $44.7M | $29.2M | $5.7M |
| Cash from operations | -$50.9M | -$48.3M | -$32.4M |
| Capital expenditure | $5.3M | $3.4M | $402,000 |
| Free cash flow | -$56.2M | -$51.7M | -$32.8M |
| Impairments | $0 | $0 | $0 |
| Total assets | $328.7M | $149.6M | $110.0M |
| Total liabilities | $41.1M | $73.6M | $51.4M |
Shares outstanding 44.6M · Free float 85.7%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.